DNA Script raises $200 million, brings breakthrough technology for every scientist
French biotechnology startup DNA Script has announced the raising of $200 million in a Series C funding round. The round was a co investment of a handful of investors with $165 million that came from Coatue Management and Catalio Capital as the leaders of this investment with participation of new and existing investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital, Moore Strategic Ventures, Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners, and Alexandria Venture Investment.
The other $35 million were a collaboration of T. Rowe Price Associates, Baillie Gifford, Healthcor Management, eureKARE, and Irving Investors. The funding is expected to be used for the development of the SYNTAX platform, a platform that is offering scientists the ability to print DNA. The company has raised a total of $315 million to date.
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy
“We are thrilled to partner with this world-class group of investors, including new participants Baillie Gifford and T. Rowe Price, who collectively share our vision to increase access to oligo manufacturing to accelerate the bio-revolution,” commented DNA Script co-founder and CEO Thomas Ybert. “SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health.”
Source: Tech.eu “French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer”